JP2024544531A5 - - Google Patents
Info
- Publication number
- JP2024544531A5 JP2024544531A5 JP2024527530A JP2024527530A JP2024544531A5 JP 2024544531 A5 JP2024544531 A5 JP 2024544531A5 JP 2024527530 A JP2024527530 A JP 2024527530A JP 2024527530 A JP2024527530 A JP 2024527530A JP 2024544531 A5 JP2024544531 A5 JP 2024544531A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- immunotherapy
- heavy chain
- protein according
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021903609 | 2021-11-11 | ||
| AU2021903609A AU2021903609A0 (en) | 2021-11-11 | Modified immunoglobulin and method of use thereof (3) | |
| AU2022901632 | 2022-06-15 | ||
| AU2022901632A AU2022901632A0 (en) | 2022-06-15 | Modified immunoglobulin and method of use thereof (3) | |
| PCT/AU2022/051287 WO2023081959A1 (en) | 2021-11-11 | 2022-10-26 | Immunotherapeutic proteins comprising an fc region component with a mutation at position 429 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024544531A JP2024544531A (ja) | 2024-12-03 |
| JP2024544531A5 true JP2024544531A5 (https=) | 2026-01-09 |
Family
ID=86334771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527530A Pending JP2024544531A (ja) | 2021-11-11 | 2022-10-26 | 位置４２９に変異を有するｆｃ領域成分を含む免疫療法タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4430084A4 (https=) |
| JP (1) | JP2024544531A (https=) |
| KR (1) | KR20240113626A (https=) |
| CN (1) | CN119421902A (https=) |
| AU (1) | AU2022387275A1 (https=) |
| WO (1) | WO2023081959A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024229535A1 (en) * | 2023-05-10 | 2024-11-14 | Macfarlane Burnet Institute For Medical Research And Public Health Limited | Immunotherapeutic proteins |
| CN121532432A (zh) * | 2023-05-10 | 2026-02-13 | 麦克法兰布奈特医疗研究与公共健康研究所有限公司 | 免疫治疗蛋白 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2016130516A1 (en) * | 2015-02-09 | 2016-08-18 | Research Development Foundation | Engineered immunoglobulin fc polypeptides displaying improved complement activation |
-
2022
- 2022-10-26 EP EP22891200.2A patent/EP4430084A4/en active Pending
- 2022-10-26 KR KR1020247019400A patent/KR20240113626A/ko active Pending
- 2022-10-26 AU AU2022387275A patent/AU2022387275A1/en active Pending
- 2022-10-26 JP JP2024527530A patent/JP2024544531A/ja active Pending
- 2022-10-26 WO PCT/AU2022/051287 patent/WO2023081959A1/en not_active Ceased
- 2022-10-26 CN CN202280084806.6A patent/CN119421902A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7662516B2 (ja) | Ｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒアルファｆｃ融合タンパク質およびその組み合わせ療法での使用 | |
| US20240209101A1 (en) | Compositions and methods related to il27 receptor binding | |
| JP7257335B2 (ja) | アンタゴニスト性ｃｄ４０モノクローナル抗体およびその使用 | |
| JP7746258B2 (ja) | 特性が改善されたｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒαｆｃ融合タンパク質 | |
| US10053517B2 (en) | Hybrid constant regions | |
| JP6647208B2 (ja) | 抗ｉｌ−１７抗体、その生産および使用のための方法 | |
| US20080166336A1 (en) | CD137 agonists to treat patients with IgE-mediated conditions | |
| CN112867734A (zh) | 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途 | |
| JP7476997B2 (ja) | 二重特異性抗体 | |
| CN119798453A (zh) | 激活免疫细胞的双特异性抗体 | |
| JP7766392B2 (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| CN108463472A (zh) | 具有修饰的j-链的结合分子 | |
| CN118852460A (zh) | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) | |
| KR20240078657A (ko) | Bcma, nkg2d 및 cd16에 결합하는 단백질 | |
| TW201803899A (zh) | 三特異性和／或三價結合蛋白 | |
| JP7754506B2 (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| KR20200038530A (ko) | Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질 | |
| US20210261654A1 (en) | Anti-il-17 antibody/tnfr ecd fusion protein and use thereof | |
| JP2024544531A5 (https=) | ||
| CA3155293A1 (en) | System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies | |
| US12540188B2 (en) | IL10Rα/IL2Rγ synthetic cytokines | |
| KR20240046224A (ko) | 이중특이성 항체 및 그 용도 | |
| WO2015113494A1 (zh) | 双功能融合蛋白及其制备方法和用途 | |
| JP7036471B2 (ja) | デスレセプター４及びデスレセプター５に結合する非常に強力な抗体 | |
| JP2024544531A (ja) | 位置４２９に変異を有するｆｃ領域成分を含む免疫療法タンパク質 |